{"id":4218,"date":"2020-09-01T22:25:00","date_gmt":"2020-09-01T22:25:00","guid":{"rendered":"https:\/\/presspart.com\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/"},"modified":"2020-09-01T22:25:00","modified_gmt":"2020-09-01T22:25:00","slug":"astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma","status":"publish","type":"post","link":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/","title":{"rendered":"Bilim Pharmaceuticals, H&#038;T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"574\" src=\"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg\" alt=\"\" class=\"wp-image-2829\" srcset=\"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg 1024w, https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1-300x168.jpg 300w, https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1-768x431.jpg 768w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">1<sup>st<\/sup>&nbsp;September 2020 \u2013&nbsp;<a href=\"http:\/\/www.bilimilac.com.tr\/\">Bilim Pharmaceuticals<\/a>, a Turkish company manufacturing and marketing pharmaceutical drugs, H&amp;T Presspart, a global provider of respiratory drug-delivery devices and components to the pharmaceutical sector, and&nbsp;<a href=\"http:\/\/www.hovionetechnology.com\/\">Hovione Technology<\/a>, a pharmaceutical specialist in the development of innovative pulmonary device technology, today unveiled a collaboration supporting Bilim Pharmaceutical\u2019s launch into the Turkish market of Ventofor Combi Fix, a formulation of Budesonide Formoterol for Asthma and COPD management, delivered by the&nbsp;<a href=\"https:\/\/www.presspart.com\/products\/powdair-plus-dry-powder-inhaler\/\">PowdAir Plus Dry Powder Inhaler (DPI)<\/a>.<\/h2>\n\n\n\n<p>Worldwide over 500 million people suffer from Asthma and COPD. In Turkey, there is growing patient demand for effective, readily accessible and affordable respiratory treatments. Aiming at fulfilling these patient needs, the three companies have been collaborating in Bilim Pharmaceuticals\u2019 development program to bring into the Turkish market Ventofor Combi Fix delivered by the PowdAir Plus DPI, an innovative capsule DPI providing maximum simplicity, ease of use and affordability. The PowdAir Plus DPI is exclusively manufactured and commercialized by H&amp;T Presspart under patent license from Hovione Technology.<\/p>\n\n\n\n<p>\u201cIt\u2019s a great pleasure for us to launch our new product Ventofor Combi Fix with a close collaboration with esteemed companies H&amp;T Presspart and Hovione Technology. As being one of the strong drivers of Asthma and COPD treatment area, Ventofor Combi Fix is and will be an important part of our portfolio for this treatment area. We are confident that Ventofor Combi Fix will be a remarkable product in its market and crown all the outstanding efforts of the collaborators\u201d, said Okan Oncel, Bilim Pharmaceuticals\u2019s General Manager.<\/p>\n\n\n\n<p>\u201cWe are very happy to see that Bilim Pharmaceuticals has selected the PowdAir Plus DPI for their launch of Ventofor Combi Fix. Due to the strong collaboration of Bilim Pharmaceuticals with Hovione Technology and H&amp;T Presspart this milestone could be reached. The individual expertise in each of their fields has allowed us to develop a strong partnership in the design, development and manufacture of PowdAir Plus. We look forward to seeing Bilim Pharmaceuticals launch the product to the market and will continue to strongly support them with their inhalation strategy.\u201d said Christian Kraetzig, H&amp;T Presspart\u2019s President.<\/p>\n\n\n\n<p>\u201cWe are delighted to have started an inhalation collaboration with Bilim Pharmaceuticals, one of Turkey\u2019s largest pharmaceutical companies, and that they selected our PowdAir Plus DPI to bring Ventofor Combi Fix to patients\u2019 hands. We are also happy to continue our partnership with H&amp;T Presspart, a master of large-scale industrialization and distribution, to turn our patented inhaler technology into a commercial ready product that is now globally available to pharmaceutical companies\u201d, said Peter Villax, Hovione Technology\u2019s CEO.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"723\" src=\"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/PowdAir-Plus-Exploded-GREY-wide-1024x723.png\" alt=\"\" class=\"wp-image-2832\" srcset=\"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/PowdAir-Plus-Exploded-GREY-wide-1024x723.png 1024w, https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/PowdAir-Plus-Exploded-GREY-wide-300x212.png 300w, https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/PowdAir-Plus-Exploded-GREY-wide-768x542.png 768w, https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/PowdAir-Plus-Exploded-GREY-wide.png 1479w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>About Bilim Pharmaceuticals<\/strong><\/p>\n\n\n\n<p>Founded in 1953, Bilim Pharmaceuticals is a 100% Turkish capital owned company that manufactures and markets drugs, a strategically important commodity. Ranked as the second largest Turkish Pharma Company in the Turkish pharmaceutical industry, Bilim Pharmaceuticals consistently continues to grow at a higher rate than the market with a marketing and sales team of app. 1000. Bilim Pharmaceuticals carries out its production activities at two separate plants. Approved by EU GMP, Bilim \u00c7erkezk\u00f6y is one of Turkey\u2019s most significant penicillin manufacturing facilities. Approved by EU GMP, Bilim Gebze is Turkey\u2019s largest, most innovative and most environment-friendly drug manufacturing plant. Bilim Pharmaceuticals owns the largest R&amp;D center of the Turkish pharmaceutical industry with a laboratory area of 4,500 square meters, where it develops new products, contributing significantly to the Turkish economy. Exporting to over 60 countries, Bilim Pharmaceuticals has representative offices in Moldova and Albania. In a sensitive sector which is directly related to human health, Bilim Pharmaceuticals prioritizes quality and adopts respect towards future generations as a corporate value.<\/p>\n\n\n\n<p><a href=\"http:\/\/www.bilimilac.com.tr\/\">www.bilimilac.com.tr<\/a><\/p>\n\n\n\n<p><strong>About H&amp;T Presspart<\/strong><\/p>\n\n\n\n<p>H&amp;T Presspart offers pharmaceutical customer\u2019s high-precision injection moulded plastic components and deep-drawn metal cans for respiratory drug delivery systems, with 50 years\u2019 experience and a worldwide reputation for competence, quality and innovation in the pharmaceutical market.&nbsp; H&amp;T Presspart\u2019s New Product Development Center (NPDC) &amp; Inhalation Product Technology Centre (IPTC) support new product developments and strategic initiatives with our customers. Founded in 1970 and acquired by the Heitkamp &amp; Thumann group in 2002, H&amp;T Presspart has 3 European manufacturing sites with additional sales offices in China, India, the U.S.A. and Uruguay. For more information, please visit&nbsp;<a href=\"http:\/\/www.presspart.com\/\">www.presspart.com<\/a>.<\/p>\n\n\n\n<p><strong>About Hovione Technology<\/strong><\/p>\n\n\n\n<p>Hovione Technology offers access to a complete portfolio of innovative, cost-effective dry powder inhalation devices \u2013 disposable, capsule-based, blister-based and large dose DPIs. With over 20 years of expertise developing innovative inhaler technology, Hovione Technology\u2019s team has been behind the first market approved disposable dry powder inhaler for influenza treatment, the TwinCaps DPI, and the new market approved capsule DPI for Asthma and COPD management, the PowdAir Plus DPI. Millions of patients are being treated every year with Hovione Technology\u2019s innovative inhaler technology. For more information, please visit&nbsp;<a href=\"http:\/\/www.hovionetechnology.com\/\">www.hovionetechnology.com<\/a>&nbsp; and contact&nbsp;<a href=\"mailto:info@hovionetechnology.com\">info@hovionetechnology.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>1st&nbsp;September 2020 \u2013&nbsp;Bilim Pharmaceuticals, a Turkish company manufacturing and marketing pharmaceutical drugs, H&amp;T Presspart, a global provider of respiratory drug-delivery devices and components to the pharmaceutical sector, and&nbsp;Hovione Technology, a pharmaceutical specialist&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[42],"tags":[],"class_list":["post-4218","post","type-post","status-publish","format-standard","hentry","category-products-and-services-de"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bilim Pharmaceuticals, H&amp;T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus - H&amp;T Presspart<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bilim Pharmaceuticals, H&amp;T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus - H&amp;T Presspart\" \/>\n<meta property=\"og:description\" content=\"1st&nbsp;September 2020 \u2013&nbsp;Bilim Pharmaceuticals, a Turkish company manufacturing and marketing pharmaceutical drugs, H&amp;T Presspart, a global provider of respiratory drug-delivery devices and components to the pharmaceutical sector, and&nbsp;Hovione Technology, a pharmaceutical specialist...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/\" \/>\n<meta property=\"og:site_name\" content=\"H&amp;T Presspart\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-01T22:25:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/presspart.in-testing.co.uk\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg\" \/>\n<meta name=\"author\" content=\"presspart\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"presspart\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/\"},\"author\":{\"name\":\"presspart\",\"@id\":\"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f\"},\"headline\":\"Bilim Pharmaceuticals, H&#038;T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus\",\"datePublished\":\"2020-09-01T22:25:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/\"},\"wordCount\":854,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg\",\"articleSection\":[\"Produkte und Dienstleistungen\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/\",\"url\":\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/\",\"name\":\"Bilim Pharmaceuticals, H&T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus - H&amp;T Presspart\",\"isPartOf\":{\"@id\":\"https:\/\/presspart.com\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg\",\"datePublished\":\"2020-09-01T22:25:00+00:00\",\"author\":{\"@id\":\"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f\"},\"breadcrumb\":{\"@id\":\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#primaryimage\",\"url\":\"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg\",\"contentUrl\":\"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/presspart.com\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bilim Pharmaceuticals, H&#038;T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/presspart.com\/de\/#website\",\"url\":\"https:\/\/presspart.com\/de\/\",\"name\":\"H&amp;T Presspart\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/presspart.com\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f\",\"name\":\"presspart\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/presspart.com\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f132ba1b1a5a3d6f3cb6529cef071eedff6082ffed6f37fb7fbbf8dde5dedb6e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f132ba1b1a5a3d6f3cb6529cef071eedff6082ffed6f37fb7fbbf8dde5dedb6e?s=96&d=mm&r=g\",\"caption\":\"presspart\"},\"sameAs\":[\"http:\/\/presspart.local\"],\"url\":\"https:\/\/presspart.com\/de\/author\/presspart\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bilim Pharmaceuticals, H&T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus - H&amp;T Presspart","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/","og_locale":"de_DE","og_type":"article","og_title":"Bilim Pharmaceuticals, H&T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus - H&amp;T Presspart","og_description":"1st&nbsp;September 2020 \u2013&nbsp;Bilim Pharmaceuticals, a Turkish company manufacturing and marketing pharmaceutical drugs, H&amp;T Presspart, a global provider of respiratory drug-delivery devices and components to the pharmaceutical sector, and&nbsp;Hovione Technology, a pharmaceutical specialist...","og_url":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/","og_site_name":"H&amp;T Presspart","article_published_time":"2020-09-01T22:25:00+00:00","og_image":[{"url":"https:\/\/presspart.in-testing.co.uk\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg","type":"","width":"","height":""}],"author":"presspart","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"presspart","Gesch\u00e4tzte Lesezeit":"4\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#article","isPartOf":{"@id":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/"},"author":{"name":"presspart","@id":"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f"},"headline":"Bilim Pharmaceuticals, H&#038;T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus","datePublished":"2020-09-01T22:25:00+00:00","mainEntityOfPage":{"@id":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/"},"wordCount":854,"commentCount":0,"image":{"@id":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#primaryimage"},"thumbnailUrl":"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg","articleSection":["Produkte und Dienstleistungen"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/","url":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/","name":"Bilim Pharmaceuticals, H&T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus - H&amp;T Presspart","isPartOf":{"@id":"https:\/\/presspart.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#primaryimage"},"image":{"@id":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#primaryimage"},"thumbnailUrl":"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg","datePublished":"2020-09-01T22:25:00+00:00","author":{"@id":"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f"},"breadcrumb":{"@id":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#primaryimage","url":"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg","contentUrl":"https:\/\/presspart.com\/wp-content\/uploads\/2022\/11\/Powdair-showcase-1024x574-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/presspart.com\/de\/astrazenecas-symbicort-turbuhaler-approved-in-china-as-an-anti-inflammatory-reliever-in-mild-asthma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/presspart.com\/de\/"},{"@type":"ListItem","position":2,"name":"Bilim Pharmaceuticals, H&#038;T Presspart and Hovione Technology unveil collaboration for new asthma product: Ventofor Combi Fix delivered by PowdAir Plus"}]},{"@type":"WebSite","@id":"https:\/\/presspart.com\/de\/#website","url":"https:\/\/presspart.com\/de\/","name":"H&amp;T Presspart","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/presspart.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/presspart.com\/de\/#\/schema\/person\/ea6faba4b50e03fce829becbe473e66f","name":"presspart","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/presspart.com\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f132ba1b1a5a3d6f3cb6529cef071eedff6082ffed6f37fb7fbbf8dde5dedb6e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f132ba1b1a5a3d6f3cb6529cef071eedff6082ffed6f37fb7fbbf8dde5dedb6e?s=96&d=mm&r=g","caption":"presspart"},"sameAs":["http:\/\/presspart.local"],"url":"https:\/\/presspart.com\/de\/author\/presspart\/"}]}},"_links":{"self":[{"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/posts\/4218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/comments?post=4218"}],"version-history":[{"count":0,"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/posts\/4218\/revisions"}],"wp:attachment":[{"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/media?parent=4218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/categories?post=4218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/presspart.com\/de\/wp-json\/wp\/v2\/tags?post=4218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}